Home LiteratureArticle Details
PMID: 14525622 Published · epublish English Evaluation Study Journal Article Research Support, Non-U.S. Gov't

The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial.

BMC medical research methodology ·Vol. 3 ·2003-10-03 ·Pages 19

Piaggio G, Elbourne D, Schulz KF, Villar J, Pinol AP, Gülmezoglu AM, WHO Research Group to evaluate Misoprostol in the Management of the Third Stage of Labour

Abstract

The aim of this article is to explore ways in which selection bias and ascertainment bias can be reduced and investigated in trials, by using the example of a drug trial carried out in both developed and developing countries in hospital delivery wards. We describe an innovative and practical design for the boxes for packing the drugs as a way of increasing the security of allocation concealment and blinding. We also assess ascertainment bias using sensitivity analyses, as some unblinding could have occurred due to a potential side effect of one of the drugs. The sensitivity analyses indicated that the conclusions about the relative effects of the treatments could be maintained even in the unlikely worst-case scenarios. Detailed description of the procedures protecting against common biases and of the assessment of ascertainment bias in this trial should allow readers to confidently appraise and interpret the results obtained. In addition, our experiences will assist others in planning trials in the future.

MeSH Terms
Developed Countries Developing Countries Double-Blind Method Female Humans Labor Stage, Third Misoprostol/adverse effects,therapeutic use Pregnancy Random Allocation Randomized Controlled Trials as Topic/methods Selection Bias World Health Organization
Chemicals
Misoprostol
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Piaggio Gilda
UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland. [email protected]
Elbourne Diana
Schulz Kenneth F
Villar José
Pinol Alain P Y
Gülmezoglu A Metin
WHO Research Group to evaluate Misoprostol in the Management of the Third Stage of Labour
References (20)
20 references, click to expand
  1. The revised CONSORT statement for reporting randomized trials: explanation and elaboration.
    Ann Intern Med. 2001 Apr 17;134(8):663-94 PMID: 11304107
  2. Misoprostol dose-related shivering and pyrexia in the third stage of labour. WHO Collaborative Trial of Misoprostol in the Management of the Third Stage of Labour.
    Br J Obstet Gynaecol. 1999 Apr;106(4):304-8 PMID: 10426235
  3. Side-effects of oral misoprostol in the third stage of labour--a randomised placebo-controlled trial.
    S Afr Med J. 2001 May;91(5):432-5 PMID: 11455810
  4. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour.
    Lancet. 2001 Sep 1;358(9283):689-95 PMID: 11551574
  5. Active-control equivalence trials and antihypertensive agents.
    Am J Med. 2001 Nov;111(7):553-8 PMID: 11705432
  6. The landscape and lexicon of blinding in randomized trials.
    Ann Intern Med. 2002 Feb 5;136(3):254-9 PMID: 11827510
  7. Generation of allocation sequences in randomised trials: chance, not choice.
    Lancet. 2002 Feb 9;359(9305):515-9 PMID: 11853818
  8. Allocation concealment in randomised trials: defending against deciphering.
    Lancet. 2002 Feb 16;359(9306):614-8 PMID: 11867132
  9. Blinding in randomised trials: hiding who got what.
    Lancet. 2002 Feb 23;359(9307):696-700 PMID: 11879884
  10. Use of misoprostol in third stage of labour.
    Lancet. 2002 Feb 23;359(9307):707-8; discussion 709-10 PMID: 11879890
  11. Use of misoprostol in third stage of labour.
    Lancet. 2002 Feb 23;359(9307):708; author reply 709-10 PMID: 11879891
  12. Use of misoprostol in third stage of labour.
    Lancet. 2002 Feb 23;359(9307):708-9; author reply 709-10 PMID: 11879892
  13. Use of misoprostol in third stage of labour.
    Lancet. 2002 Feb 23;359(9307):709; author reply 709-10 PMID: 11879893
  14. Unequal group sizes in randomised trials: guarding against guessing.
    Lancet. 2002 Mar 16;359(9310):966-70 PMID: 11918933
  15. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.
    JAMA. 1995 Feb 1;273(5):408-12 PMID: 7823387
  16. Misoprostol for third stage of labour.
    Lancet. 1996 May 4;347(9010):1257 PMID: 8622464
  17. Improving the quality of reporting of randomized controlled trials. The CONSORT statement.
    JAMA. 1996 Aug 28;276(8):637-9 PMID: 8773637
  18. Randomised trials, human nature, and reporting guidelines.
    Lancet. 1996 Aug 31;348(9027):596-8 PMID: 8774577
  19. Use of oral misoprostol in the prevention of postpartum haemorrhage.
    Br J Obstet Gynaecol. 1997 Mar;104(3):336-9 PMID: 9091012
  20. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.
    Lancet. 2001 Apr 14;357(9263):1191-4 PMID: 11323066
Article Info
Journal
BMC medical research methodology
Abbr.
BMC Med Res Methodol
ISSN
1471-2288
Published
2003-10-03
Epub
2003-00-03
Pages
19
Language
English
Region
England
NLM ID
100968545
PMCID
PMC280677
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]